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rtM250V.
In the clinical context of antiviral drug resistance, treating
physicians need to adopt therapeutic strategies that
effectively control viral replication in the ﬁrst place, but
if treatment failure does occur, then a knowledge of cross-
resistance is needed in order to tailor appropriate “add-on”
therapy. Finally, the role of host genetics in inﬂuencing the
outcome of HBV disease in the context of natural history and
therapy is beginning to aid understanding in pathogenesis
and, when this knowledge is linked to pathogen-speciﬁc
databases, this should translate into more individualised
and effective patient care.
Concurrent Session 10: Management of CHB
Factors and Trends
Saturday, July 16, 2011, 13:30 15:00
Meeting Room 310
CS10.1 Current approaches and potential strategies:
Avoid and manage drug resistance
Abstract not available
CS10.2 HBsAg seroconversion as treatment endpoint:
Phenomenon and reality
J.L. Hou*. Hepatology Unit, Nanfang Hospital, Guangzhou,
China
Abstract not available
CS10.3 A better clinical practice through quantitative
HBsAg levels
J.Y. Park*. Department of Internal Medicine, Yonsei
University College of Medicine; Liver Cirrhosis Clinical
Research Center, Seoul, Korea
Despite the availability of effective vaccines, chronic
hepatitis B (CHB) remains a signiﬁcant health burden
worldwide. In clinical ﬁelds, hepatitis B surface antigen
(HBsAg) has long served as a qualitative diagnostic marker
for HBV infection. HBsAg seroclearance is considered the
closest-to-cure outcome of hepatitis B virus infection,
reﬂecting immunological control of infection. Recently,
retrospective and prospective studies have shown that
HBsAg levels change along the natural history of CHB, and
that HBsAg levels in patients undergoing antiviral therapy
suggest a role for HBsAg quantitation in monitoring response
to therapy. There is increasing evidence that baseline
HBsAg levels and HBsAg kinetics during antiviral therapy
are predictive of treatment result. Notably, advances have
been made in the development of quantitative HBsAg assays,
which have allowed viral replication monitoring, and there
is an opportunity to make maximal use of quantitative HBsAg
to elucidate its role in clinical ﬁelds. Quantitative HBsAg
appear to be very promising as baseline and early on-
treatment predictors of sustained viral suppression and
HBsAg clearance. Further studies are required to validate
the use of these tools.
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In order to meet the global target of controlling tuberculosis
(TB), much emphasis has been placed on the development of
new tools for the purpose, to complement the enhancement
of existing programmatic activities in various countries
and geographical regions worldwide. The development of
new tools can be divided into 4 main areas. The ﬁrst
area is concerned with advances in the diagnosis of
TB and rapid assessment of drug susceptibility of the
Mycobacterium tuberculosis strains causing the disease.
The new tools developed ultilize the molecular approach or
phenotypic methods. A quite signiﬁcant recent development
has been that of a commercially available tool that rapidly
detects the presence of M. tuberculosis in the sputum
specimen, alongside performance of drug susceptibility
testing, especially to rifampicin. This apparently robust
test requires minimal manual skill, and appears readily
applicable at the point of care. However, it is clear
that the availability of new diagnostic tools does not
necessarily equate to their adoption, the translation of
policy into practice requires identiﬁcation of obstacles
and their resolution. Regarding the development of new
anti-tuberculosis drugs which constitutes the second area,
quite a number of new compounds are on the horizon.
Several are in Phase II and Phase III of clinical trials. Aside
from the rifamycins already in use, the diarylquinoline,
nitroimidazoles and the newer ﬂuoroquinolones appear to
hold the highest promise for clinical application in TB
treatment in the near future. Other potentially useful
compounds might include the ethylenediamines and the
oxazolidinones. Despite the encouraging progress, there
remains the important challenge of lack of global clinical
trial capacity to support the new drugs developed to gain
timely registration. The third area is clearly related to
TB vaccine development. The only TB vaccine available
for use today is bacillus Calmette Guerin which needs
improvement. There is an urgent need for developing a
modern, safe and effective TB vaccine to prevent all
forms of disease, in all age groups and among people
with HIV infection. Several vaccine candidates are now
in Phase II clinical development. The most promising ones
appear to be the recombinant forms of BCG, other live
mycobacterial vaccines and vaccines based on genetic
attenuation of M. tuberculosis. The last area is connected
with the development of biomarkers for monitoring disease
activity and predicting the outcome of TB treatment.
The advancement in this area has been relatively tardy.
Hopefully a combination of biomarkers might address the
issue better. It is clear that much more work is still required
here. Thus the past decade has witnessed a renaissance of
activities in the development of new tools for achieving
TB control globally. The fruitful outcome of these activities
have furnished high hopes for better control of TB, the
formidable foe of mankind, in the decade to come.
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Efforts to control the global TB epidemic have been
hampered by the lack of accurate and rapid diagnostic
